AF
ACRS icon

Allworth Financial’s Aclaris Therapeutics ACRS Stock Holding History

Allworth Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461 Buy
87
+38
+78% +$169 ﹤0.01% 4862
2026
Q1 		$184 Buy
+49
New +$165 ﹤0.01% 4937
2023
Q4 		– Sell
-38
Closed -$261 – 3451
2023
Q3 		$261 Buy
+38
New +$325 ﹤0.01% 3194

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Allworth Financial's ACRS Position: Q2 2026 in Review

Allworth Financial increased its Aclaris Therapeutics (ACRS) stake by 78% in Q2 2026, buying an estimated $169 and bringing the position to 87 shares worth $461. The position accounts for ﹤0.01% of the portfolio, ranked #4862.

Allworth Financial first reported a position in ACRS in Q3 2023 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Allworth Financial held 87 shares of Aclaris Therapeutics worth $461 as of Q2 2026.
  • Allworth Financial bought 38 Aclaris Therapeutics shares in Q2 2026, an estimated $169.
  • Aclaris Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4862 holding.
  • Allworth Financial first reported a position in Aclaris Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.